SCHEMBL22802736

SCHEMBL22802736

CSC(C)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 1/20 0.47
TSHR P16473 1/20 0.46
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 1/20 0.43
KCNA5 P22460 6/20 0.43
EHMT2 Q96KQ7 1/20 0.43
EHMT1 Q9H9B1 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
KCNH2 Q12809 1/20 0.43
KCNE1 P15382 2/20 0.41
CYP2D6 P10635 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
CHRM2 P08172 1/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL951054 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3TSHRCYP1A2
SCHEMBL8723764 0.84 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3TSHRCYP1A2
SCHEMBL18627209 0.81 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3TSHRCYP1A2
SCHEMBL10297526 0.81 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3TSHRCYP1A2
Ammonia Solution, Strong SCHEMBL25305692 0.79 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3TSHRCYP1A2
Ammonia Solution, Strong SCHEMBL7995788 0.79 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3TSHRCYP1A2
SCHEMBL15196292 0.78 KCNA5 (0.47) SLC6A2SLC6A4SLC6A3TSHRCYP1A2
Hydrochloric Acid SCHEMBL19814627 0.77 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3TSHRCYP1A2
SCHEMBL79529 0.77
SCHEMBL725091 0.77 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3TSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265100-A1 RIP1K INHIBITORS RIGEL PHARMACEUTICALS, INC. 2023-08-24 US disclosed
US-11136316-B2 Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the Human Immunodeficiency Virus YALE UNIVERSITY (US) 2021-10-05 US disclosed
US-20200392121-A1 BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-12-17 US disclosed
US-20190070172-A1 LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS IMAGO BIOSCIENCES, INC. 2019-03-07 US disclosed
US-20180192651-A1 THERMAL VOLATILIZATION OF ORCO AGONISTS VANDERBILT UNIVERSITY 2018-07-12 US disclosed
CN-104222135-B Stable insecticide compositions 美国陶氏益农公司 2017-04-26 CN disclosed
US-9079890-B2 Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives ARRAY BIOPHARMA INC. (US) 2015-07-14 US disclosed
US-20150057448-A1 INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES ARRAY BIOPHARMA, INC. 2015-02-26 US disclosed
CN-104222135-A Stable insecticide compositions DOW AGROSCIENCES LLC 2014-12-24 CN disclosed
US-8883828-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2014-11-11 US disclosed
US-8853409-B2 Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus ARRAY BIOPHARMA INC. (US) 2014-10-07 US disclosed
US-20130065901-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2013-03-14 US disclosed
US-8354540-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2013-01-15 US disclosed
US-8212045-B2 Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus ARRAY BIOPHARMA, INC. (US) 2012-07-03 US disclosed
US-20110281874-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2011-11-17 US disclosed
US-8022223-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20100204240-A1 Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus ARRAY BIOPHARMA INC. (US) 2010-08-12 US disclosed
CN-101778857-A Platinum (IV) complex compound PLATCO TECHNOLOGIES PROPRIETAR 2010-07-14 CN disclosed
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPPHARMA INC. (US) 2010-04-29 US disclosed
US-20090156603-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265100-A1 RIP1K INHIBITORS RIPK1, RIPK2, RIPK3 SLC6A2 4877/4885SLC6A4 4872/4885SLC6A3 4832/4885
US-20200392121-A1 BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS CD4, HAVCR2, CD2 SLC6A2 1888/4885SLC6A4 3820/4885SLC6A3 2795/4885
US-20180192651-A1 THERMAL VOLATILIZATION OF ORCO AGONISTS OR51E2, OR10J3, TRPA1 SLC6A2 1182/4885SLC6A4 580/4885SLC6A3 988/4885
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 SLC6A2 1836/4885SLC6A4 2031/4885SLC6A3 2057/4885
US-20090156603-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, PRKCSH SLC6A2 2533/4885SLC6A4 2637/4885SLC6A3 3126/4885
US-20190070172-A1 LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS KDM1B, KDM1A, KDM2A SLC6A2 3976/4885SLC6A4 4369/4885SLC6A3 4345/4885
US-11136316-B2 Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the Human Immunodeficiency Virus CD4, HAVCR2, CD2 SLC6A2 1888/4885SLC6A4 3820/4885SLC6A3 2795/4885
US-20150057448-A1 INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES PDXK, IL4I1, CDK2 SLC6A2 3556/4885SLC6A4 2855/4885SLC6A3 3156/4885
US-20130065901-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 SLC6A2 1836/4885SLC6A4 2031/4885SLC6A3 2057/4885
US-20110281874-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 SLC6A2 1836/4885SLC6A4 2031/4885SLC6A3 2057/4885
US-20100204240-A1 Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus PDXK, GCKR, GCK SLC6A2 4348/4885SLC6A4 3867/4885SLC6A3 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.